• | Sitemap
• | Contact
• Home

Spectral Diagnostics Inc

• Spectral
  • Company Overview
  • Management
  • Board of Directors
  • Events
• Sepsis & endotoxin
  • Sepsis & Endotoxin
  • EUPHRATES Trial
  • Trial FAQ
• Products
  • Products Overview
  • EAA^TM
  • Toraymyxin
  • Reagents
• Investors
  • Investors Overview
  • News & Media
  • Press Releases
  • Financial Reports
  • Regulatory Filings
  • Corporate Governance
  • Stock Information
  • Investor FAQ
  • Investor Sign Up
  • Contact
• Resources
  • Sepsis Links
  • Publications

Spectral Diagnostics CEO Dr. Paul Walker Discusses the Company’s Phase III Sepsis Asset, and the Plan of Arrangement